Funding in 2011: East Heats Up as West Cools Down  by Macilwain, Colin
Leading Edge
AnalysisFunding in 2011: East Heats Up
as West Cools DownThe great slowdown in the global economy since 2008 is putting
the brakes on government spending for health research funding
worldwide. Could this be an opportunity for research centers in
Asia to shift the power balance?For the past decade, global investment in
biomedical research, both basic and clin-
ical, has surged forward. The United
States doubled the budget of the National
Institutes of Health (NIH) between 1998
and 2003, and many other governments
have eagerly supported the life sciences,
sometimes at the expense of other areas
of research.
But inOctober 2008, the banking system
collapsed and knocked the stuffing out of
government balance sheets. Since then,
eagerness for funding biomedical researchhas stalled. And, according to analysts and
senior researchers in the fifteen largest
scientific powers, funding will go into
reverse during 2011. With stories of deep
cuts circulating, the atmosphere in many
labs is one of alarm.
However, a closer look at budget plans
shows that governments aren’t axing
spending, but rather retrenching. In fact,
most nations are protecting science from
steeper cuts applied to other areas of
public spending. TheUnited States, which
utterly dominates global spending onCell 144biomedical research, and Britain, which
has energetically sought leadership in
some areas of it, will each try to maintain
spending at 2010 levels this year, even in
the face of huge budgetary pressures.
That said, some mid-sized players,
including Italy, Spain, Canada, and
Australia, have already cut back their
spending since 2008. And Singapore is
sharply reorientating its program by di-
verting 30% of its planned biomedical
research spending to partnerships with
industry. Other nations are pressing their
researchers to generate visible results,
fast.
But the frigid funding outlook isn’t
global. Scientific powers with strong
export industries have been protected
from the spending slump, as China,
Korea, India, and Germany are planning
substantial increases in the spending on
biomedical research for 2011.
Apples and Oranges
International comparisons of health
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difficult. Most nations lack a dominant
agency akin to the US’s NIH, supporting
both laboratory and clinical research.
Many nations pay researchers’ salaries
out of nonresearch budgets, and their
basic research efforts aren’t easily allo-
cated to specificmissions, such as health.
Thus, the world’s main repositories of
research statistics—the OECD (Organisa-
tion for European Economic Cooperation)
in Paris, Eurostat in Luxembourg, and the
US National Science Foundation in Arling-
ton, Virginia—struggle to agree on what
constitutes health research spending.
Nevertheless, spending on biomedical
research is heavily skewed toward weal-
thy countries in general and the US in
particular. According to an exhaustive
2007 study by the European Medical
Research Councils, the US spends $40
billion annually. This is 2–3 times as
much as the European Union, which in
turn spends significantly more than the
rest of the world combined.
But could this balance of power be
shifting? A rapid-fire global tour of the
world’s largest spenders reveals the
beginnings of a swing in government
spending on biomedical research, with
investments in Asia surging forward,
although admittedly from a low base.
2012—NIH’s Year of Reckoning
The outlook for the United States typifies
the global picture in developed countries.
Although the current financial year for the
US began in October 2010, Congress isn’t
expected to complete the 2011 budget
until this March. Until then, spending is
frozen at last year’s level of $31 billion,
and any adjustment is likely to be down-
wards. The newly elected House of
Representatives, now under the Republi-
can’s control, will try to cut the budget,
perhaps by $2 billion, and the biomedical
research lobby will be looking to its allies
in the Senate to protect it.
This means that, in the most optimistic
scenario, the actual value of the NIH
budget will fall by 3% in 2011, once
inflation is taken into account. Obama
will propose his budget for 2012 this
February, before the 2011 budget is
even complete, and Congress is again ex-
pected to try and reduce whatever
number he proposes.
Every nation’s research budget has its
quirks, and the biggest one for the US168 Cell 144, January 21, 2011 ª2011 Elsevieright now is the continuing impact of Mr.
Obama’s stimulus package, which in-
jected an additional $10 billion into NIH
in February 2009. Most of the money will
be spent in 2010 and 2011, according to
the Federation of American Societies for
Experimental Biology. It will supplement
core funding in each year by over $4
billion. ‘‘Really the key pressure point for
NIH is the 2012 financial year,’’ says
Jennifer Zeitzer, legislative director at
the FASEB.
The strategy in Canada appears similar:
hold funding steady, at best. A decade
ago, Canada tried hard to assert itself in
the biomedical sphere by establishing
the Canadian Institutes of Health
Research. But after rapid growth initially,
its budget has plateaued at about CN
$930 million (US $940 million) in 2007
and 2008. Last year, Canada’s budget
rose by 1.5%, and according to Mark
Henderson, the editor of Canadian news-
letter Research Money, it is ‘‘highly
unlikely’’ to do better in 2011.
Funding in Australia also grew quickly
over the last decade. However, the
budget for the National Health and
Medical Research Council in Australia
peaked at AU $714 million in 2009, and it
has been frozen ever since. ‘‘The outlook
for next year looks bleak,’’ says Julie
Campbell, a biologist at the University of
Queensland and president of the Associa-
tion of Australian Medical Research Insti-
tutes. ‘‘There certainly is no hope for an
increase, with a real threat that it may be
decreased.’’
Asia Surges Forward
In Asia, the picture is quite different.
Korea’s spending in areas related to
biotechnology powered ahead from less
than US $100 million in 1998 to $850
million in 2008 and $1.25 billion in 2010.
This money comes from three separate
government departments and goes to
both basic and clinical research. Accord-
ing to researchers and government offi-
cials, Korea’s funding will probably keep
growing at a compound rate of around
20%.
India has experienced a massive boom
in private-sector research and develop-
ment since 2005, when it transformed its
large pharmaceutical industry by reform-
ing its patent laws. Moreover, the Indian
government is preparing to increase ther Inc.combined budget for its biotechnology
and science departments (US $700
million) by more than 20% this year.
China’s budgets are notoriously opa-
que, and details of its research spending
don’t feature in the OECD’s international
comparisons. Nonetheless, China’s
biomedical spending has been growing
relentlessly, probably close to the annual
compound rate that the Chinese report
for research and development—an
impressive 22.6% per year.
Yet China’s efforts have to be kept in
perspective. From 2006–2008, for
example, China spent just 11.9 billion
Yuan (US $1.8 billion) on research aimed
at health and agriculture combined (see
UNESCO report). Assuming China invests
the same again on other basic research
related to health, this puts China’s invest-
ment in biomedical research just above
Korea’s and still considerably below that
of Japan.
Early last month, Reuters published an
unconfirmed report that China might
invest an astounding $1.5 trillion dollars
in seven high-tech industry sectors—
including biotechnology—under its five
year plan for 2011–2015. Such leaks are
used habitually in China to signal intent
rather than to plan budgets. And, in the
past, China has put agriculture ahead of
health as a biotechnology priority. None-
theless, the announcement offers a taste
of what could lie ahead if China’s
economy continues to expand.
Perhaps the world’s most audacious
experiment in building a biomedical
researchhub fromscratchhas takenplace
in Singapore. In 2000, Singapore estab-
lished the BioMedical Research Council
(BMRC), which offered large, unfettered
grants for basic research. This strategy
has developed a significant research
capability, drawing significant global
attention and attracting a large number of
talented scientists in areas such as stem
cell research. However, in September
2010, the government announced that its
approach will change. The amount of
money available for biomedical research
will grow slightly in 2011–2015, to SI $3.7
billion (US $2.8 billion), but 30% of that
will be available only for collaborations
with drug companies.
‘‘The money will be distributed in a
different way,’’ says George Radda, chair
of the BMRC. ‘‘The government is
expecting researchers to show some re-
turns for its investment.’’ The priority shift
came after a governmental study found
that investments in engineering research
provided stronger economic returns for
Singapore. ‘‘The principles are not bad,’’
comments one leading biologist in
Singapore. ‘‘But the execution will be
a challenge.’’
Japanese public spending on biomed-
ical research, which is split between
several agencies, has grown slowly over
the past decade. Now it totals about 340
billion yen (US $4 billion). Its 2011 budget
hadn’t been agreed at the time of writing,
but it was expected to be flat or slightly
down, according to analysts in Japan.
Deutsche Boom, Euro Gloom
Of the major European nations, only
Germany is planning a significant expan-
sion for biomedical funding in 2011. The
science ministry will increase funding by
7%, and an additionalV300million is allo-
cated to translational work. So the total
biomedical budget could grow by as
much as 11% in 2011.France has also backed the life
sciences over the last few years, though
less emphatically than Germany. French
politicians traded barbs last October
over whether the total 2011 research
budget across all agencies was actually
up or down. But, nevertheless, the main
biomedical agency in France, Inserm, will
receive a 4.3% funding increase this year.
After taking a swinging 14% cut last
year, Spanish researchers are breathing
a small sigh of relief in 2011—their
science and innovation ministry is being
protected from an austerity budget now
pushing through the legislature. But the
atmosphere in universities in southern
Europe is still downbeat. Like colleagues
in Italy, who experienced double-digit
cuts across all disciplines last year,
Spanish researchers are worried that their
prospects of catching up with neighbors
in northern Europe are receding, perhaps
for good. ‘‘The situation in Italy is dismal,’’
says Ramon Marimon, a former Spanish
science secretary currently working as
an economist in Florence, ‘‘and it has
been for some time.’’Cell 144In conclusion, nations whose econo-
mies have held up since the 2008 finan-
cial crisis may be rewarded in 2011
with an opportunity to make inroads
into the established biomedical order. If
Asia’s economic resurgence and scien-
tific renaissance continue, a real change
in the global balance of power in
biomedical research could indeed tran-
spire. But these future scientific power-
houses still have a lot of ground to cover
to approach the funding levels of the
United States.Web Resources
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